

Clinical trials of eplerenone

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
eplerenone vs placebo			
EMPHASIS-HF , 2010 [NCT00232180] n=1364/1373 follow-up: 21 months	eplerenone versus placebo	patients with New York Heart Association class II heart failure and an ejection fraction of no more than 35%	Parallel groups double blind 29 countries
EPHESUS , 2003 n=3319/3313 follow-up: 16 mo (mean, range 0 to 33)	eplerenone 25 mg per day initially, titrated to a maximum of 50 mg per day versus placebo	patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure	Parallel groups Double blind 37 countries
REMODEL ongoing [NCT00082589] n=NA follow-up:	Eplerenone versus placebo	Patients with left ventricular systolic dysfunction (EF Less Than or Equal to 35%) and mild to moderate heart failure	Parallel groups double blind
Weir ongoing [NCT00132093] n=NA follow-up: 6 montsh	eplerenone versus placebo	patients with acute myocardial infarction	Parallel groups double blind

More details and results :

- diuretics for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q75>
- diuretics for heart failure in Left Ventricular Dysfunction after Myocardial Infarction at <http://www.trialresultscenter.org/go-Q76>
- aldosterone blockade for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q488>

References

EMPHASIS-HF, 2010:

Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010;12:617-22 [20388647] [10.1093/eurjhf/hfq049](https://doi.org/10.1093/eurjhf/hfq049)

Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B Rationale and design of the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail 2010;12:617-22 [20388647] [10.1093/eurjhf/hfq049](https://doi.org/10.1093/eurjhf/hfq049)

Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2010 Nov 14;: [21073363] 10.1056/NEJMoa1009492

EPHESUS, 2003:

Pitt B, White H, Nicolau J, Martinez F, Gheorghiuade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005 Aug 2;46:425-31 [16053953]

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 Apr 3;348:1309-21 [12668699]

REMODEL, :

ongoing trial NCT00082589

Weir, :

ongoing trial NCT00132093

Entry terms: eplerenon, Inspra